Suppr超能文献

维甲酸在肺癌化学预防和治疗中的应用。

Retinoids in lung cancer chemoprevention and treatment.

作者信息

Toma S, Raffo P, Isnardi L, Palumbo R

机构信息

Department of Medical Oncology, University of Genova, Italy.

出版信息

Ann Oncol. 1999;10 Suppl 5:S95-102. doi: 10.1093/annonc/10.suppl_5.s95.

Abstract

In this review, we aim to synthesize the emerging picture of retinoids in lung cancer through a summary of ongoing investigations in biology, chemoprevention and therapy settings, in an attempt to clarify the possible role of these agents in such a disease. Early work in head and neck cancer has evidenced the capability of retinoids to interrupt field carcinogenesis by reversing premalignant lesions and decreasing the incidence of second primary tumors (SPTs). At this time, the completed randomized trials in lung cancer have failed to demonstrate an evident chemopreventive effect of the tested agents on different study end points, although both a marginally significant benefit of retinol palmitate in time-to-development rates for smoke-related SPTs and a potential preventive effect of retinol supplementation against mesothelioma in selected populations of asbestos-exposed workers have been recently reported. Concerning the role of retinoids in lung cancer treatment, a moderate activity of 13-cis-retinoic acid (13cRA) or all-transretinoic acid (ATRA) as single agents has been reported in small series of advanced, mostly pretreated lung cancer patients. More encouraging findings derive from combination studies, in which retinoids, especially ATRA, are added to either alpha-interferon or chemotherapy and radiotherapy. Major recent advances have been made towards the understanding of retinoids mechanisms of action; at this regard, the role of RAR-beta basal or treatment-induced levels seems to be of particular interest as intermediate end point and/or independent prognostic factor, besides their known importance in lung carcinogenesis. Future research for chemopreventive and therapeutic programs with retinoids in lung cancer should be focused on the investigation of new generation compounds with a specificity for individual retinoid nuclear receptors. Such selective molecules may have a greater activity against lung cancer, with a more favourable toxicity profile, as recently suggested by our preliminary data on Ro 41-5253.

摘要

在本综述中,我们旨在通过总结生物学、化学预防和治疗方面正在进行的研究,综合呈现视黄酸在肺癌中的新情况,以阐明这些药物在该疾病中可能发挥的作用。头颈部癌症的早期研究已证明视黄酸能够通过逆转癌前病变和降低第二原发性肿瘤(SPT)的发生率来中断场致癌作用。目前,肺癌的完整随机试验未能证明受试药物对不同研究终点有明显的化学预防作用,尽管最近有报道称,棕榈酸视黄酯在与吸烟相关的SPT的发生时间率方面有略微显著的益处,并且在选定的石棉暴露工人人群中,补充视黄醇对间皮瘤有潜在的预防作用。关于视黄酸在肺癌治疗中的作用,在一小部分晚期(大多为经预处理的)肺癌患者中,已报道13 - 顺式维甲酸(13cRA)或全反式维甲酸(ATRA)作为单一药物有适度的活性。更令人鼓舞的发现来自联合研究,其中视黄酸,尤其是ATRA,被添加到α - 干扰素或化疗及放疗中。最近在对视黄酸作用机制的理解方面取得了重大进展;在这方面,RAR - β基础水平或治疗诱导水平的作用似乎特别值得关注,因为它们除了在肺癌发生中已知的重要性外,还作为中间终点和/或独立预后因素。未来关于视黄酸在肺癌化学预防和治疗方案中的研究应集中于对新一代对个体视黄酸核受体具有特异性的化合物的研究。正如我们最近关于Ro 41 - 5253的初步数据所表明的,这种选择性分子可能对肺癌有更大的活性,且毒性特征更有利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验